Fat poetry: A kingdom for PPARγ

Cell Research

Volumn 17, Issue 6, 2007, Pages 486-511

  Anghel, Silvia I ^a   Wahli, Walter ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

adipose tissue; energy homeostasis; obesity; peroxisome proliferator activated receptor

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADIPOSE TISSUE; ANIMAL; ENERGY METABOLISM; HOMEOSTASIS; HUMAN; METABOLISM; OBESITY; PHYSIOLOGY; REVIEW;

ADIPOSE TISSUE; ANIMALS; ENERGY METABOLISM; HOMEOSTASIS; HUMANS; OBESITY; PPAR GAMMA;

EID: 34250803903     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/cr.2007.48     Document Type: Review

References (254)

1. Romijn JA, Fliers E. Sympathetic and parasympathetic innervation of adipose tissue: metabolic implications. Curr Opin Clin Nutr Metab Care 2005; 8:440-444.
2. McMillan DC, Sattar N, McArdle CS. ABC of obesity. Obesity and cancer. BMJ 2006; 333:1109-1111.
3. Mandrup, S, Lane MD. Regulating adipogenesis. J Biol Chem 1997; 272:5367-5370.
4. Juge-Aubry CE, Somm E, Giusti V, et al. Adipose tissue is a major source of interleukin-1 receptor antagonist: upregulation in obesity and inflammation. Diabetes 2003; 52:1104-1110.
5. Fruhbeck G, Gomez-Ambrosi J, Muruzabal FJ and Burrell MA The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am J Physiol Endocrinol Metab 2001; 280:E827-E847.
6. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998; 83:847-850.
7. Cinti S. The adipose organ. Prostaglandins Leukot Essent Fatty Acids 2005; 73:9-15.
8. Hansen JB, Kristiansen K. Regulatory circuits controlling white versus brown adipocyte differentiation. Biochem J 2006; 398:153-168.
9. Avram AS, Avram MM, James WD. Subcutaneous fat in normal and diseased states: 2. Anatomy and physiology of white and brown adipose tissue. J Am Acad Dermatol 2005; 53:671-683.
10. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20:649-688.
11. Rosen ED, MacDougald OA. Adipocyte differentiation from the inside out. Nat Rev Mol Cell Biol 2006; 7:885-896.
12. Gimble JM, Zvonic S, Floyd ZE, Kassem M, and Nuttall ME. Playing with bone and fat. J Cell Biochem 2006; 98:251-266.
13. Crane JF, PA Trainor PA. Neural crest stem and progenitor cells. Annu Rev Cell Dev Biol 2006; 22:267-286.
14. Cinti S. The adipose organ: morphological perspectives of adipose tissues. Proc Nutr Soc 2001; 60:319-328.
15. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000; 21:697-738.
16. Gesta S, Bluher M, Yamamoto Y, et al. Evidence for a role of developmental genes in the origin of obesity and body fat distribution. Proc Natl Acad Sci USA 2006; 103:6676-6681.
17. Pouliot MC Despres JP, Nadeau A, et al. Visceral obesity in men. Associations with glucose tolerance, plasma insulin, and lipoprotein levels. Diabetes 1992; 41:826-834.
18. Despres JP, Nadeau A, TremblayA, et al. Role of deep abdominal fat in the association between regional adipose tissue distribution and glucose tolerance in obese women. Diabetes 1989; 38:304-309.
19. He Q, Engelson ES, DP Kotler DP. A comparison of abdominal subcutaneous adipose tissue pattern in obese and lean HIV-infected women. J Nutr 2005; 135:53-57.
20. Klein S, Fontana L, Young VL, et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med 2004; 350:2549-2557.
21. Thorne A, Lonnqvist F, Apelman J, Hellers G, and Arner P. A pilot study of long-term effects of a novel obesity treatment: omentectomy in connection with adjustable gastric banding. Int J Obes Relat Metab Disord 2002; 26:193-199.
22. Laviola L, Perrini S, Cignarelli A, et al. Insulin signaling in human visceral and subcutaneous adipose tissue in vivo. Diabetes 2006; 55:952-961.
23. ParkHS, Lee K. Greater beneficial effects of visceral fat reduction compared with subcutaneous fat reduction on parameters of the metabolic syndrome: a study of weight reduction programmes in subjects with visceral and subcutaneous obesity. Diabet Med 2005; 22:266-272.
24. Misra A, NK Vikram NK. Clinical and pathophysiological consequences of abdominal adiposity and abdominal adipose tissue depots. Nutrition 2003; 19:457-466.
25. Greenberg AS, Egan JJ, Wek SA, Moos MC Jr, Londos C, and Kimmel AR. Isolation of cDNAs for perilipins A and B: sequence and expression of lipid droplet-associated proteins of adipocytes. Proc Natl Acad Sci USA 1993; 90:12035-12039.
26. Rosen ED, Spiegelman BM. Adipocytes as regulators of energy balance and glucose homeostasis. Nature 2006; 444:847-853.
27. Gibbons G. Old fat, make way for new fat. Nat Med 2005; 11:722-723.
28. Arner P. Human fat cell lipolysis: biochemistry, regulation and clinical role. Best Pract Res Clin Endocrinol Metab 2005; 19:471-4782.
29. Wang Y, Wang PY, Takashi K. Chronic effects of different non-esterified fatty acids on pancreatic islets of rats. Endocrine 2006; 29:169-173.
30. Joseph JW, Koshkin V, Saleh MC, et al. Free fatty acid-induced beta-cell defects are dependent on uncoupling protein 2 expression. J Biol Chem 2004; 279:51049-51056.
31. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature, 2006; 444:881-887.
32. Ahima RS, Qi Y, Singha, NS, Jackson MB, and Scherer PE. Brain adipocytokine action and metabolic regulation. Diabetes, 2006; 55 Suppl 2:S145-S154.
33. Verreth W, De Keyzer D, Pela M, et al. Weight-loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice. Circulation 2004; 110:3259-3269.
34. Ronti T, Lupattelli G, Mannarino E. The endocrine function of adipose tissue: an update. Clin Endocrinol (Oxf) 2006; 64:355-365.
35. Klein J, Perwitz N, Kraus D, and Fasshauer M. Adipose tissue as source and target for novel therapies. Trends Endocrinol Metab 2006; 17:26-32.
36. Juge-Aubry CE, Henrichot E, Meier CA. Adipose tissue: a regulator of inflammation. Best Pract Res Clin Endocrinol Metab 2005; 19:547-566.
37. Hutley L, Prins JB. Fat as an endocrine organ: relationship to the metabolic syndrome. Am J Med Sci 2005; 330:280-289.
38. Guerre-Millo M. Adipose tissue and adipokines: for better or worse. Diabetes Metab 2004; 30:13-19.
39. Halaas JL, Gajiwala KS, Maffei M, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995; 269:543-546.
40. Frederich RC, HamannA, Anderson S, Lollmann B, Lowell BB, and Flier JS. Leptin levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action. Nat Med 1995; 1:1311-1314.
41. Unger RH. Hyperleptinemia: protecting the heart from lipid overload. Hypertension 2005; 45:1031-1034.
42. Wang MY, Orci L, Ravazzola M, and Unger RH. Fat storage in adipocytes requires inactivation of leptin's paracrine activity: implications for treatment of human obesity. Proc Natl Acad Sci USA 2005; 102:18011-18016.
43. Kershaw EE, JS Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89:2548-2556.
44. Ebihara K, Kusakabe T, Hirata M, et al. Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. J Clin Endocrinol Metab 2007; 92:532-541.
45. Pelleymounter MA, Cullen MJ, Baker MB. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995; 269:540-543.
46. Heymsfield SB, Greenberg AS, Fujioka K, et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 1999; 282:1568-1575.
47. Flores-Morales A, Greenhalgh CJ, Norstedt G, and Rico-Bautista E. Negative regulation of growth hormone receptor signaling. Mol Endocrinol, 2006; 20:241-253.
48. Farooqi IS, Matarese G, Lord GM, et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 2002; 110:1093-1103.
49. Akirav EM, Chan O, Inouye K, Riddell MC, Matthews SG, and Vranic M. Partial leptin restoration increases hypothalamicpituitary-adrenal activity while diminishing weight loss and hyperphagia in streptozotocin diabetic rats. Metabolism 2004; 53:1558-1564.
50. Lloyd RV, Jin L, Tsumanuma I, et al. Leptin and leptin receptor in anterior pituitary function. Pituitary 2001; 4:33-47.
51. Kamei N, Tobe K, Suzuki R, et al. Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J Biol Chem 2006; 281:26602-26614.
52. Hug C, Wang J, Ahmad NS, Bogan JS, Tsao TS, and Lodish HF. T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci USA 2004; 101:10308-10313.
53. Okamoto Y, Kihara S, Funahashi T, Matsuzawa Y, and Libby P. Adiponectin: a key adipocytokine in metabolic syndrome. Clin Sci (Lond) 2006; 110:267-278.
54. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7:941-946.
55. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8:1288-1295.
56. Hotta K, Funahashi T, Bodkin NL, Ortmeyer HK, Arita Y, et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 2001; 50:1126-1133.
57. Yatagai T, Nagasaka S, Taniguchi A, et al. Hypoadiponectinemia is associated with visceral fat accumulation and insulin resistance in Japanese men with type 2 diabetes mellitus. Metabolism 2003; 52:1274-1278.
58. Steppan CM, Brown EJ, Wright CM, et al. A family of tissue-specific resistin-like molecules. Proc Natl Acad Sci USA 2001; 98:502-506.
59. Banerjee RR, Rangwala SM, Shapiro JS, et al. Regulation of fasted blood glucose by resistin. Science 2004; 303:1195-1198.
60. Patel SD, Rajala MW, Rossetti L, Scherer PE, and Shapiro L. Disulfide-dependent multimeric assembly of resistin family hormones. Science 2004; 304:1154-1158.
61. Kusminski CM, McTernan PG, Kumar S. Role of resistin in obesity, insulin resistance and type II diabetes. Clin Sci (Lond) 2005; 109:243-256.
62. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001; 409:307-312.
63. Fain JN, Cheema PS, Bahouth SW, and Lloyd Hiler M. Resistin release by human adipose tissue explants in primary culture. Biochem Biophys Res Commun 2003; 300:674-678.
64. Nagaev I, Smith U. Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem Biophys Res Commun 2001; 285:561-564.
65. Savage DB, Sewter CP, Klenk ES, et al. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 2001; 50:2199-2202.
66. Patel L, Buckels AC, Kinghom IJ, et al. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 2003; 300:472-476.
67. Kielstein JT, Becker B, Graf S, Brabant G, Haller H, and Fliser D. Increased resistin blood levels are not associated with insulin resistance in patients with renal disease. Am J Kidney Dis 2003; 42:62-66.
68. Banerjee RR, MA Lazar MA. Resistin: molecular history and prognosis. J Mol Med 2003; 81:218-226.
69. Kersten S. Regulation of lipid metabolism via angiopoietin-like proteins. Biochem Soc Trans 2005; 33Part 5:1059-1062.
70. Kim I, Kim HG, Kim H, et al. Hepatic expression, synthesis and secretion of a novel fibrinogen/angiopoietin-related protein that prevents endothelial-cell apoptosis. Biochem J 2000; 346 Part 3:603-610.
71. Puigserver P, Rhee J, Lin J, et al. Cytokine Stimulation of energy expenditure through p38 MAP kinase activation of PPARgamma coactivator-1. Mol Cell 2001; 8:971-982.
72. Kersten S, Mandard S, Tan NS, et al. Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene. J Biol Chem 2000; 275:28488-28493.
73. Hara K, Okada T, Tobe K, et al. The Pro12Ala polymorphism in PPAR gamma2 may confer resistance to type 2 diabetes. Biochem Biophys Res Commun 2000; 271:212-216.
74. Xu A, Lam MC, Chan KW, et al. Angiopoietin-like protein 4 decreases blood glucose and improves glucose tolerance but induces hyperlipidemia and hepatic steatosis in mice. Proc Natl Acad Sci USA 2005; 102:6086-6091.
75. Mandard S, Zandbergen F, van Straten E, et al. The fasting-induced adipose factor/angiopoietin-like protein 4 is physically associated with lipoproteins and governs plasma lipid levels and adiposity. J Biol Chem 2006; 281:934-944.
76. Lee K, Villena JA, Moon YS, et al. Inhibition of adipogenesis and development of glucose intolerance by soluble preadipocyte factor-1 (Pref-1). J Clin Invest 2003; 111:453-461.
77. Greenberg AS, MS Obin MS. Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr 2006; 83:461S-465S.
78. YuYH, Ginsberg HN. Adipocyte signaling and lipid homeostasis: sequelae of insulin-resistant adipose tissue. Circ Res 2005; 96:1042-1052.
79. Yang RZ, Lee MJ, Hu H, Pollin TI, et al. Acute-phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications. PLoS Med 2006; 3:e287.
80. Kahn SE, Zinman B, Haffner SM, et al. Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes. Diabetes 2006; 55:2357-2364.
81. Pajvani UB, Trujillo ME, Combs TP, et al. Fat apoptosis through targeted activation of caspase 8: a new mouse model of inducible and reversible lipoatrophy. Nat Med 2005; 11:797-803.
82. Sadler D, Mattacks CA, CM Pond CM. Changes in adipocytes and dendritic cells in lymph node containing adipose depots during and after many weeks of mild inflammation. J Anat 2005; 207:769-781.
83. Wellen KE, GS Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 2003; 112:1785-1788.
84. Hotamisligil GS, Shargill NS, BM Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259:87-91.
85. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444:860-867.
86. Weisberg SP, Hunter D, Huber R, et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 2006; 116:115-124.
87. Winkler G, Kiss S, Keszthelyi L, et al. Expression of tumor necrosis factor (TNF)-alpha protein in the subcutaneous and visceral adipose tissue in correlation with adipocyte cell volume, serum TNF-alpha, soluble serum TNF-receptor-2 concentrations and C-peptide level. Eur J Endocrinol 2003; 149:129-135.
88. Bullo M, Garcia-Lorda P, Peinado-Onsurbe J, et al. TNFalpha expression of subcutaneous adipose tissue in obese and morbid obese females: relationship to adipocyte LPL activity and leptin synthesis. Int J Obes Relat Metab Disord 2002; 26:652-658.
89. Prins JB, Niesler CU, Winterford CM, et al Tumor necrosis factor-alpha induces apoptosis of human adipose cells. Diabetes 1997; 46:1939-1944.
90. Ruan H, Miles PD, Ladd CM, et al. Profiling gene transcription in vivo reveals adipose tissue as an immediate target of tumor necrosis factor-alpha: implications for insulin resistance. Diabetes 2002; 51:3176-3188.
91. Cheung AT, Ree D, Kolls JK, Fuselier J, Coy DH, and Bryer-Ash M. An in vivo model for elucidation of the mechanism of tumor necrosis factor-alpha (TNF-alpha)-induced insulin resistance: evidence for differential regulation of insulin signaling by TNF-alpha. Endocrinology 1998; 139:4928-4935.
92. Van der Poll T, Romijn JA, Endert E, Borm JJ, Buller HR, and Sauerwein H P. Tumor necrosis factor mimics the metabolic response to acute infection in healthy humans. Am J Physiol 1991; 261(4 Part 1):E457-E465.
93. Zhang YH, Lin JX, Vilcek J. Interleukin-6 induction by tumor necrosis factor and interleukin-1 in human fibroblasts involves activation of a nuclear factor binding to a kappa B-like sequence. Mol Cell Biol 1990; 10:3818-3823.
94. Bastard JP, Maachi M, Van Nhieu JT, et al. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab 2002; 87:2084-2089.
95. Keller P, Penkowa M, Keller C, et al. Interleukin-6 receptor expression in contracting human skeletal muscle: regulating role of IL-6. FASEB J 2005; 19:1181-1183.
96. Janssen SP, Gayan-Ramirez G, Van den Bergh A, et al. Interleukin-6 causes myocardial failure and skeletal muscle atrophy in rats. Circulation 2005; 111:996-1005.
97. Klover PJ, Zimmers TA, Koniaris LG, and Mooney RA. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 2003; 52:2784-2789.
98. Scaglione R, Argano C, di Chiara T, et al. Central obesity and hypertensive renal disease: association between higher levels of BMI, circulating transforming growth factor betal and urinary albumin excretion. Blood Press 2003; 12:269-276.
99. Fain JN, Tichansky DS, Madan AK. Transforming growth factor betal release by human adipose tissue is enhanced in obesity. Metabolism 2005; 54:1546-1551.
100. Alessi MC, Bastelica D, Morange P, et al. Plasminogen activator inhibitor 1, transforming growth factor-beta 1, and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes 2000; 49:1374-1380.
101. Cancello R, Henegar C, Viguerie N, et al. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes 2005; 54:2277-2286.
102. Christiansen T, Richelsen B, Bruun JM. Monocyte chemoattractant protein-1 is produced in isolated adipocytes, associated with adiposity and reduced after weight loss in morbid obese subjects. Int J Obes (Lond) 2005; 29:146-150.
103. Sell H, Dietze-Schroeder D, Kaise U, and Eckel J. Monocyte chemotactic protein-1 is a potential player in the negative cross-talk between adipose tissue and skeletal muscle. Endocrinology 2006; 147:2458-2467.
104. Kanda H, Tateya S, Tamori Y, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006; 116:1494-1505.
105. Pandey M, Loskutoff DJ, Samad F. Molecular mechanisms of tumor necrosis factor-alpha-mediated plasminogen activator inhibitor-1 expression in adipocytes. FASEB J 2005; 19:1317-1319.
106. Juhan-Vague I, Alessi MC, Mavri A, and Morange PE. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost 2003; 1:1575-1579.
107. Alessi MC, Juhan-Vague I. PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vase Biol 2006; 26:2200-2207.
108. Loskutoff DJ, Samad F. The adipocyte and hemostatic balance in obesity: studies of PAI-1. Arterioscler Thromb Vase Biol 1998; 18:1-6.
109. Lundgren CH, Brown SL, Nordt TK, Sobel BE, and Fujii S. Elaboration of type-1 plasminogen activator inhibitor from adipocytes. A potential pathogenetic link between obesity and cardiovascular disease. Circulation 1996; 93:106-110.
110. Skurk T, Hauner H. Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. Int J Obes Relat Metab Disord 2004; 28:1357-1364.
111. Samad F, Pandey M, Loskutoff DJ. Tissue factor gene expression in the adipose tissues of obese mice. Proc Natl Acad Sci USA 1998; 95:7591-7596.
112. Zhang Y, Deng Y, Luther T, et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 1994; 94:1320-1327.
113. Dormandy JA, Charbonnel B, Eckland D J, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro Vascular Events): a randomised controlled trial. Lancet 2005; 366:1279-1289.
114. Prasad A, Quyyumi AA. Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome. Circulation 2004; 110:1507-1512.
115. Turgeon JL, Carr MC, Maki PM, Mendelsohn ME, and Wise PM. Complex actions of sex steroids in adipose tissue, the cardiovascular system, and brain: insights from basic science and clinical studies. Endocr Rev 2006; 27:575-605.
116. Farnier C, Krief S, Blache M, et al. Adipocyte functions are modulated by cell size change: potential involvement of an integrin/ERK signalling pathway. Int J Obes Relat Metab Disord 2003; 27:1178-1186.
117. DiGirolamo M, Fine JB, Tagra K, and Rossmanith R. Qualitative regional differences in adipose tissue growth and cellularity in male Wistar rats fed ad libitum. Am J Physiol 1998; 274(5 Part 2):R1460-R1467.
118. Bastard JP, Maachi M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Networks 2006; 17:4-12.
119. Suganami T, Nishida J, Ogawa Y. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. Arterioscler Thromb Vase Biol 2005; 25:2062-2068.
120. Neels JG, Olefsky JM. Inflamed fat: what starts the fire? J Clin Invest 2006; 116:33-35.
121. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003; 112:1821-1830.
122. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, and Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112(12):1796-1808.
123. Clement K, Viguerie N, Poitou C, et al. Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects. FASEB J 2004; 18:1657-1669.
124. Cinti S, Mitchell G, Barbatelli G, et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 2005; 46:2347-2355.
125. Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci USA 2003; 100:7265-7270.
126. Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, and Pratley RE. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res 2001; 9:414-417.
127. Clement K. Genetics of human obesity. C R Biol 2006; 329:608-622; discussion 653-655.
128. Simha V, Garg A. Lipodystrophy: lessons in lipid and energy metabolism. Curr Opin Lipidol 2006; 17: 162-169.
129. Chun TH, Hotary KB, Sabeh F, Saltiel AR, Allen ED, and Weiss SJ. Apericellular collagenase directs the 3-dimensional development of white adipose tissue. Cell 2006; 125: 577-5791.
130. Shackleton S, Lloyd DJ, Jackson SN, et al LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nat Genet 2000; 24:153-156.
131. Morel CF, Thomas MA, Cao H, et al. A LMNA splicing mutation in two sisters with severe Dunnigan-type familial partial lipodystrophy type 2. J Clin Endocrinol Metab 2006; 91:2689-2695.
132. Hegele RA, Kraw ME, Ban MR, Miskie B A, Huff MW, and Cao H. Elevated serum C-reactive protein and free fatty acids among nondiabetic carriers of missense mutations in the gene encoding lamin A/C (LMNA) with partial lipodystrophy. Arterioscler Thromb Vase Biol 2003; 23:111-116.
133. Hegele RA, Anderson CM, Wang J, Jones DC, and Cao H. Association between nuclear lamin A/C R482Q mutation and partial lipodystrophy with hyperinsulinemia, dyslipidemia, hypertension, and diabetes. Genome Res 2000; 10:652-658.
134. Wong SP, Huda M, English P, et al. Adipokines and the insulin resistance syndrome in familial partial lipodystrophy caused by a mutation in lamin A/C. Diabetologia 2005; 48:2641-2649.
135. Lundin C, Nordstrom R, Wagner K, et al. Membrane topology of the human seipin protein. FEBS Lett 2006; 580:2281-2284.
136. Magre J, Delepine M, Van Maldergem L, et al. Prevalence of mutations in AGPAT2 among human lipodystrophies. Diabetes 2003; 52:1573-1578.
137. Fischer-Posovszky P, Hebestreit H, Hofmann AK, et al. Role of CD95-mediated adipocyte loss in autoimmune lipodystrophy. J Clin Endocrinol Metab 2006; 91:1129-1135.
138. Domingo P, Vidal F, Domingo JC, et al. Tumour necrosis factor alpha in fat redistribution syndromes associated with combination antiretroviral therapy in HIV-1-infected patients: potential role in subcutaneous adipocyte apoptosis. Eur J Clin Invest 2005; 35:771-780.
139. Jan V, Cervera P, Maachi M, et al. Altered fat differentiation and adipocytokine expression are inter-related and linked to morphological changes and insulin resistance in HIV-1-infected lipodystrophic patients. Antivir Ther 2004; 9:555-564.
140. Domingo P, Matias-Guiu X, Pujol RM, et al. Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy. Aids 1999; 13:2261-2267.
141. Imai T, Takakuwa R, Marchand S, et al. Peroxisome proliferator-activated receptor gamma is required in mature white and brown adipocytes for their survival in the mouse. Proc Natl Acad Sci USA 2004; 101:4543-4547.
142. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351:1106-1118.
143. Agarwal AK, Garg A. A novel heterozygous mutationinperoxisome proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy. J Clin Endocrinol Metab 2002; 87:408-411.
144. Dreyer C, Krey G, Keller H, Givel F, Helftenbein G, and Wahli W. Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell 1992; 68:879-887.
145. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990; 347:645-650.
146. Feige JN, Gelman L, Michalik L, Desvergne B, and Wahli W. From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res 2006; 45: 120-159.
147. Marques BG, Hausman DB, Martin RJ. Association of fat cell size andparacrine growth factors in development of hyperplastic obesity. Am J Physiol 1998; 275(6 Part 2):R1898-R1908.
148. Garaulet M, Hernandez-Morante JJ, Lujan J, Tebar FJ, and Zamora S. Relationship between fat cell size and number and fatty acid composition in adipose tissue from different fat depots in overweight/obese humans. Int J Obes (Lond) 2006; 30:899-905.
149. Crossno JT, Majka SM, Grazia T, Gill RG, and Klemm DJ. Rosiglitazone promotes development of a novel adipocyte population from bone marrow-derived circulating progenitor cells. J Clin Invest 2006; 116:3220-3228.
150. Hausman GJ, Hausman DB. Search for the preadipocyte progenitor cell. J Clin Invest 2006; 116:3103-3106.
151. Chawla A, Schwarz EJ, Dimaculangan DD, and Lazar MA. Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology 1994; 135:798-800.
152. Escher P, Braissant o, Basu-Modak S, Michalik L, Wahli W, and Desvergne B. Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology 2001; 142:4195-4202.
153. Rahimian R, Masih-Khan E, Lo M, van Breemen C, McManus BM, and Dube G P. Hepatic over-expression of peroxisome proliferator activated receptor gamma2 in the ob/ob mouse model of non-insulin dependent diabetes mellitus. Mol Cell Biochem 2001; 224:29-37.
154. Tontonoz P, Hu E, Graves RA, Budavari AI, and Spiegelman BM. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 1994; 8:1224-1234.
155. Lehrke M, Lazar MA. The many faces of PPARgamma. Cell 2005; 123:993-999.
156. Gerhold DL, Liu F, Jiang G, et al. Gene expression profile of adipocyte differentiation and its regulation by peroxisome proliferator- activated receptor-gamma agonists. Endocrinology 2002; 143:2106-2118.
157. Ross SE, Erickson RL, Gerin I, et al. Microarray analyses during adipogenesis: understanding the effects of Wnt signaling on adipogenesis and the roles of liver X receptor alpha in adipocyte metabolism. Mol Cell Biol 2002; 22:5989-5999.
158. Patel YM, Lane MD. Mitotic clonal expansion during preadipocyte differentiation: calpain-mediated turnover of p27. J Biol Chem 2000; 275:17653-17660.
159. Hosono T, Mizuguchi H, Katayama K, et al. RNA interference of PPARgamma using fiber-modified adenovirus vector efficiently suppresses preadipocyte-to-adipocyte differentiation in 3T3-L1 cells. Gene 2005; 348:157-165.
160. Rosen ED, Sarraf P, Troy AE, et al PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 1999; 4:611-617.
161. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 1994; 79:1147-1156.
162. Farmer SR. Transcriptional control of adipocyte formation. Cell Metab 2006; 4:263-273.
163. Way JM, Harrington WW, Brown KK, et al. Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. Endocrinology 2001; 142:1269-1277.
164. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, et al PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 1996; 15:5336-5348.
165. Avallone R, Demers A, Rodrigue-Way A, et al. A growth hormone-releasing peptide that binds scavenger receptor CD36 and ghrelin receptor upregulates ABC sterol transporters and cholesterol efflux in macrophages through a PPAR {gamma}-dependent pathway. Mol Endocrinol 2006; 20:3165-78.
166. Martin G, Poirier H, Hennuyer N, et al. Induction of the fatty acid transport protein 1 and acyl-CoA synthase genes by dimer-selective rexinoids suggests that the peroxisome proliferator-activated receptor-retinoid X receptor heterodimer is their molecular target. J Biol Chem 2000; 275:12612-12618.
167. Bogacka I, Xie H, Bray GA, and Smith SR. The effect of pioglitazone on peroxisome proliferator-activated receptor-gamma target genes related to lipid storage in vivo. Diabetes Care 2004; 27:1660-1667.
168. Schachtrup C Emmler T, Bleck B, Sandqvist A, and Spener F. Functional analysis of peroxisome-proliferator-responsive element motifs in genes of fatty acid-binding proteins. Biochem J 2004; 382(Part 1):239-245.
169. Ranganathan G, Unal R, Pokrovskaya I, et al The lipogenic enzymes DGAT1, FAS, and LPL in adipose tissue: effects of obesity, insulin resistance, and TZD treatment. J Lipid Res 2006; 47:2444-2450.
170. Dalen KT, Schoonjans K, Ulven SM, et al. Adipose tissue expression of the lipid droplet-associating proteins S3-12 and perilipin is controlled by peroxisome proliferator-activated receptor-gamma. Diabetes 2004; 53:1243-1252.
171. Patsouris D, Mandard S, Voshol PJ, et al PPARalpha governs glycerol metabolism. J Clin Invest 2004; 114:94-103.
172. Olswang Y, Cohen H, Papo O, et al A mutation in the peroxi-some proliferator-activated receptor gamma-binding site in the gene for the cytosolic form of phosphoenolpyruvate carboxykinase reduces adipose tissue size and fat content in mice. Proc Natl Acad Sci USA 2002; 99:625-630.
173. Guan HP, Li Y, Jensen MV, Newgard CB, Steppan CM, and Lazar MA. A futile metabolic cycle activated in adipocytes by antidiabetic agents. Nat Med 2002; 8:1122-1128.
174. Tontonoz P, Hu E, Devine J, Beale EG, and Spiegelman BM. PPAR gamma 2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene. Mol Cell Biol 1995; 15:351-357.
175. Riserus U, Tan GD, Fielding B A et al. Rosiglitazone increases indexes of stearoyl-CoA desaturase activity in humans: link to insulin sensitization and the role of dominant-negative mutation in peroxisome proliferator-activated receptor-gamma. Diabetes 2005; 54:1379-1384.
176. Barak Y, Nelson MC, Ong ES, et al. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell 1999; 4:585-595.
177. Duan SZ, Ivashchenko CY, Whitesall SE, et al. Hypotension, lipodystrophy, and insulin resistance in generalized PPARgamma-deficient mice rescued from embryonic lethality. J Clin Invest 2007; 117:812-822.
178. Rieusset J, Seydoux J, Anghel SI, et al. Altered growth in male peroxisome proliferator-activated receptor gamma (PPARgamma) heterozygous mice: involvement of PPARgamma in a negative feedback regulation of growth hormone action. Mol Endocrinol, 2004; 18:2363-2377.
179. Yamauchi T, Kamon J, Waki H, et al. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J Biol Chem 2001; 276:41245-41254.
180. Miles PD, Barak Y, He W, Evans RM, and Olefsky JM. Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. J Clin Invest 2000; 105:287-292.
181. Kubota N, Terauchi Y, Miki H, et al. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 1999; 4:597-609.
182. He W, Barak Y, Hevener A, et al. Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci USA 2003; 100:15712- 15717.
183. Freedman BD, Lee EJ, Park Y, and Jameson JL. A dominant negative peroxisome proliferator-activated receptor-gamma knock-in mouse exhibits features of the metabolic syndrome. J Biol Chem 2005; 280:17118-17125.
184. Jones JR, Barrick C, Kim KA, et al. Deletion of PPARgamma in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance. Proc Natl Acad Sci USA 2005; 102:6207-6212.
185. Zhang J, Fu M, Cui T, et al. Selective disruption of PPARgamma 2 impairs the development of adipose tissue and insulin sensitivity. Proc Natl Acad Sci USA 2004; 101:10703-10708.
186. Koutnikova H, Cock TA, Watanabe M, et al. Compensation by the muscle limits the metabolic consequences of lipodystrophy in PPAR gamma hypomorphic mice. Proc Natl Acad Sci USA 2003; 100:14457-14462.
187. Chao L, Marcus-Samuel s B, Mason MM, et al. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J Clin Invest 2000; 106:1221-1228.
188. Gavrilova 0, Haluzik M, Matsusue K, et al. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem 2003; 278:34268-34276.
189. Kim JK, Fillmore JJ, Gavrilova O, et al. Differential effects of rosiglitazone on skeletal muscle and liver insulin resistance in A-ZIP/F-1 fatless mice. Diabetes 2003; 52:1311-1318.
190. Ailhaud G. Adipose tissue as a secretory organ: from adipogenesis to the metabolic syndrome. C R Biol 2006; 329: 570-577; discussion 653-655.
191. Savage DB, Tan GD, Acerini CL, et al. Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptorgamma. Diabetes 2003; 52:910-917.
192. Agostini M, Gurnell M, Savage DB, et al. Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor gamma. Endocrinology 2004; 145:1527-1538.
193. Hegele RA, Cao H, Frankowski C, Mathews ST, and Leff T. PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy. Diabetes 2002; 51:3586-3590.
194. Altshuler D, Hirschhorn JN, Klannemark M, et al. The common PPARgamma Pro 12A1a polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000; 26:76-80.
195. Deeb SS, Fajas L, Nemoto M, et al. A Pro12A1a substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998; 20:284-287.
196. Meirhaeghe A, Fajas L, Helbecque N, et al. Impact of the peroxisome proliferator: activated receptor gamma2 Pro1A1a polymorphism on adiposity, lipids and non-insulin-dependent diabetes mellitus. Int J Obes Relat Metab Disord 2000; 24:195-199.
197. Clement K, Hercberg S, Passinge B, et al. The Prol 115Gln and Prol2Ala PPAR gamma gene mutations in obesity and type 2 diabetes. Int J Obes Relat Metab Disord 2000; 24:391-393.
198. Mancini FP, Vaccaro O, Sabatino L, et al. Pro12A1a substitution in the peroxisome proliferator-activated receptor-gamma2 is not associated with type 2 diabetes. Diabetes 1999; 48:1466-1468.
199. Florez JC, Hirschhorn J, Altshuler D. The inherited basis of diabetes mellitus: implications for the genetic analysis of complex traits. Annu Rev Genomics Hum Genet 2003; 4:257-291.
200. Weedon MN, McCarthy MI, Hitman G, et al. Combining information from common type 2 diabetes risk polymorphisms improves disease prediction. PLoS Med 2006; 3:e374.
201. Desvergne B, Michalik L, Wahli W. Be fit or be sick: peroxisome proliferator-activated receptors are down the road. Mol Endocrinol 2004; 18:1321-1332.
202. Hamer OW, Forstner D, Ottinger I, et al. The Prol 115Gln polymorphism within the PPAR gamma2 gene has no epidemiological impact on morbid obesity. Exp Clin Endocrinol Diabetes 2002; 110:230-234.
203. Hiragun A, Sato M, Mitsui H. Preadipocyte differentiation in vitro: identification of a highly active adipogenic agent. J Cell Physiol 1988; 134:124-130.
204. Fujita T, Sugiyama Y, Taketomi S, et al. Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylc yclohexylmethoxy)benzyl]-thiazolidine-2,4-dione(ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent. Diabetes 1983; 32:804-810.
205. Lazar MA. PPAR gamma, 10 years later. Biochimie 2005; 87:9-13.
206. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM and Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995; 270:12953-12956.
207. Todd MK, Watt MJ, Le J, Hevener AL, and Turcotte LP. Thiazolidinediones enhance skeletal muscle triacylglycerol synthesis while protecting against fatty acid-induced inflammation and insulin resistance. Am J Physiol Endocrinol Metab 2007; 292: E485-E493.
208. Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87:2784-2791.
209. Bastard JP, Hainque B, Dusserre E, et al. Peroxisome proliferator activated receptor-gamma, leptin and tumor necrosis factor-alpha mRNA expression during very low calorie diet in subcutaneous adipose tissue in obese women. Diabetes Metab Res Rev 1999; 15:92-98.
210. Ludtke A, Heck K, Genschel J, et al. Long-term treatment experience in a subject with Dunnigan-type familial partial lipodystrophy: efficacy of rosiglitazone. Diabet Med 2005; 22:1611-1613.
211. van Wijk JP, de Koning EJ, Cabezas MC, et al. Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial. Ann Intern Med 2005; 143:337-346.
212. Sarafidis PA, Lasaridis AN. Actions of peroxisome proliferatoractivated receptors-gamma agonists explaining a possible blood pressure-lowering effect. Am J Hypertens 2006; 19:646-653.
213. Hetzel J, Balletshofer B, Rittig K, et al. Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arterioscler Thromb Vase Biol 2005; 25:1804-1809.
214. Boden G, Homko C, Mozzoli M, Showe LC, Nichols C, and Cheung P. Thiazolidinediones upregulate fatty acid uptake and oxidation in adipose tissue of diabetic patients. Diabetes 2005; 54:880-885.
215. Laplante M, Festuccia WT, Soucy G, et al. Mechanisms of the depot specificity of peroxisome proliferator-activated receptor gamma action on adipose tissue metabolism. Diabetes 2006; 55:2771-2778.
216. Nesto RW, Bell D, Bonow RO, et al Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003; 108:2941-2948.
217. Lebovitz HE, Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab Res Rev 2002; 18 Suppl 2:S23-S29.
218. Guan Y, Hao C, Cha DR, et al Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 2005; 11:861-866.
219. Delea TE, Edelsberg JS, Hagiwara M, Oster G, and Phillips LS. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care 2003; 26:2983-2989.
220. Lygate CA, Hulbert K, Monfared M, et al. The PPARgamma-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction. Cardiovasc Res 2003; 58:632-637.
221. Nakano R, Kurosaki E, Yoshida S, et al. Antagonism of peroxisome proliferator-activated receptor gamma prevents high-fat diet-induced obesity in vivo. Biochem Pharmacol 2006; 72:42-52.
222. Rieusset J, Touri F, Michalik L, et al. A new selective peroxisome proliferator-activated receptor gamma antagonist with antiobesity and antidiabetic activity. Mol Endocrinol 2002; 16:2628-2644.
223. Yamauchi T, Waki H, Kamon J, et al. Inhibition of RXR and PEARgamma ameliorates diet-induced obesity and type 2 diabetes. J Clin Invest 2001; 108:1001-1013.
224. Wright HM, Clish CB, Mikami T, et al. A synthetic antagonist for the peroxisome proliferator-activated receptor gamma inhibits adipocyte differentiation. J Biol Chem 2000; 275:1873-1877.
225. McDonnell DP. Mechanism-based discovery as an approach to identify the next generation of estrogen receptor modulators. FASEB J 2006; 20:2432-2434.
226. Schupp M, Clemenz M, Gineste R, et al. Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes 2005; 54:3442-3452.
227. Berger JP, Petro AE, Macnaul KL, et al. Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. Mol Endocrinol 2003; 17:662-676.
228. Gurnell M, Savage DB, Chatterjee VK, and O'Rahilly S. The metabolic syndrome: peroxisome proliferator-activated receptor gamma and its therapeutic modulation. J Clin Endocrinol Metab 2003; 88:2412-2421.
229. Wang M, Tafuri S. Modulation of PPARgamma activity with pharmaceutical agents: treatment of insulin resistance and atherosclerosis. J Cell Biochem 2003; 89:38-47.
230. Sporn MB, Suh N, Mangelsdorf DJ. Prospects for prevention and treatment of cancer with selective PPARgamma modulators (SPARMs). Trends Mol Med 2001; 7:395-400.
231. Jordan VC, Morrow M. Tamoxifen, raloxifene, and the prevention of breast cancer. Endocr Rev 1999; 20:253-278.
232. Rocchi S, Picard F, Vamecq J, et al. A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol Cell 2001; 8:737-747.
233. Liu K, Black RM, Acton JJ, et al Selective PPARgamma modulators with improved pharmacological profiles. Bioorg Med Chem Lett 2005; 15:2437-2440.
234. Acton JJ III, Black RM, Jones AB, et al. Benzoyl 2-methyl indoles as selective PPARgamma modulators. Bioorg Med Chem Lett 2005; 15:357-362.
235. Allen T, Zhang F, Moodie SA, et al. Halofenate is a selective peroxisome proliferator-activated receptor gamma modulator with antidiabetic activity. Diabetes 2006; 55:2523-2533.
236. Picard F, Kurtev M, Chung N, et al. Sirt 1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 2004; 429:771-776.
237. Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006; 444:337-342.
238. Lagouge M, Argmann C, Gerhart-Hines Z, et al. Resveratrol improves mitochondrial function and protects against meta-bolic disease by activating SIRT1 and PGC-1alpha. Cell 2006; 127:1109-1122.
239. Cohen HY, Miller C, Bitterman KJ, et al. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 2004; 305:390-392.
240. Tortora GJ, Grawsik SR, eds. Principes d'anatomie et de physiologie. 3rd Edition. Bruxelles: DeBoek Université, 2001:1252.
241. Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307:426-430.
242. Van Harmelen V, Reynisdottir S, Cianflone K, et al. Mechanisms involved in the regulation of free fatty acid release from isolated human fat cells by acylation-stimulating protein and insulin. J Biol Chem 1999; 274:18243-18251.
243. Yang Q, Graham TE, Mody N, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005; 436:356-362.
244. Hida K, Wada J, Eguchi J, et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci USA 2005; 102:10610-10615.
245. Yang RZ, Lee MJ, Hu H, et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006; 290:E1253-E1261.
246. Sorhede Winzell M, Magnusson C, Ahren B. The apj receptor is expressed in pancreatic islets and its ligand, apelin, inhibits insulin secretion in mice. Regul Pept 2005; 131:12-17.
247. Fain JN, Madan AK, Hiler ML, Cheema P, and Bahouth SW. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004; 145:2273-82.
248. Somm E, Cettour-Rose P, Asensio C, et al. Interleukin-1 receptor antagonist is upregulated during diet-induced obesity and regulates insulin sensitivity in rodents. Diabetologia 2006; 49:387-393.
249. Straczkowski M, Dzienis-Straczkowska S, Stepien A, Kowalska I, Szelachowska M, and Kinalska I. Plasma interleukin-8 concentrations are increased in obese subjects and related to fat mass and tumor necrosis factor-alpha system. J Clin Endocrinol Metab 2002; 87:4602-4606.
250. Herder C, Haastert B, Muller-Scholze S, et al. Association of systemic chemokine concentrations with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg Survey S4 (KORA S4). Diabetes 2005; 54 Suppl 2:S11-S17.
251. Herder C, Hauner H, Kempf K, Kolb H, and Skurk T. Constitutive and regulated expression and secretion of interferon-gamma-inducibleprotein 10 (P-10/CXCL10) inhuman adipocytes. Int J Obes (Lond) 2006; 31:403-410.
252. Karlsson C, Lindell K, Ottosson M, Sjostrom L, Carlsson B, and Carlsson LM. Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II. J Clin Endocrinol Metab 1998; 83:3925-3929.
253. Massiera F, Bloch-Faure M, Ceiler D, et al. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J2001; 15:2727-2729.
254. Berg AH, PE Scherer. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005; 96:939-949.